Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02420860 · ClinicalTrials.gov registry record · Phase 2

Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

A Phase 2 study of Plasma Cell Myeloma and Hematopoietic Cell Transplantation Recipient, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 2
Development phase
113
Enrollment target
1
Study location

NCT02420860 is a Phase 2 study of Plasma Cell Myeloma and Hematopoietic Cell Transplantation Recipient that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 113 participants, below the 205-participant average among 32 other Plasma Cell Myeloma trials with a reported enrollment target (45% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02420860, a Phase 2 study of Plasma Cell Myeloma and Hematopoietic Cell Transplantation Recipient, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
113 participants
Enrollment target
1
Study location

Study Summary

This phase II trial studies how well elotuzumab works when given with lenalidomide as maintenance therapy after transplant in patients with newly diagnosed multiple myeloma who underwent transplant using their own stem cells (autologous transplant). Maintenance therapy is treatment that is given to help keep cancer from coming back after it has disappeared following the initial treatment. Immunotherapy with monoclonal antibodies, such as elotuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Biological therapies, such as lenalidomide, may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Adding elotuzumab to standard maintenance therapy with lenalidomide may work better in treating patients with multiple myeloma who have undergone transplant.

Conditions Studied

Plasma Cell Myeloma Hematopoietic Cell Transplantation Recipient

Interventions

  • OTHER Questionnaire Administration
  • DRUG Lenalidomide
  • BIOLOGICAL Elotuzumab

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 113 participants
Start Date 2015-04-14
Est. Completion 2027-04-30
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02420860

The ClinicalTrials.gov registry entry for NCT02420860 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 32 other Plasma Cell Myeloma trials with a reported enrollment target (45% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Plasma Cell Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Questionnaire Administration is the first listed.

NCT02420860 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02420860 about?

NCT02420860 is a clinical study titled "Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma". This phase II trial studies how well elotuzumab works when given with lenalidomide as maintenance therapy after transplant in patients with newly diagnosed multiple myeloma who underwent transplant using their own stem cells (autologous transplant). Maintenance therapy is treatment that is given to ...

What is the current status of trial NCT02420860?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 113 participants. The study started on 2015-04-14. Estimated completion is 2027-04-30.

What conditions does trial NCT02420860 study?

This clinical trial studies the following conditions: Plasma Cell Myeloma, Hematopoietic Cell Transplantation Recipient.

What interventions are being tested in trial NCT02420860?

The interventions under investigation include: Questionnaire Administration (OTHER), Lenalidomide (DRUG), Elotuzumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT02420860?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02420860 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Plasma Cell Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Plasma Cell Myeloma

All registered trials for this condition

Hematopoietic Cell Transplantation Recipient

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.